Pfizer Will Collaborate With Beam Therapeutics For In Vivo Base Editing

Pfizer Will Collaborate With Beam Therapeutics For In Vivo Base Editing

Today, Pfizer Inc. and Beam Therapeutics Inc., a biotechnology company developing precision genetic medicines through base editing, announced an exclusive four-year research collaboration focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. Investors should note Pfizer will pay Beam $300 million up … Read more

Arc Institute Emerges After Two Years Of Development

Arc Institute Emerges After Two Years Of Development

Arc Institute is a nonprofit research organization headquartered in Palo Alto, California. Arc is an independent institute that operates in collaboration with Stanford University, the University of California, Berkeley, and the University of California, San Francisco. According to Arc, biomedical innovation in areas such as mRNA technology, gene editing, and cell therapies suggest that historic … Read more

STEM Jobs: Fastest-Growing Occupations

STEM Jobs: Fastest-Growing Occupations

The number of STEM jobs — science, technology, engineering and mathematics — is in a secular growth storm, having sped past the number of non-STEM jobs by three times since 2000. Students pursuing STEM education will be positioned to benefit from the wave of innovations in synthetic biology. And experts say there might not be enough graduates in those fields to fill … Read more

AbbVie, Biogen and Pfizer Create World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants

AbbVie, Biogen and Pfizer Create World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants

Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie, Biogen Inc. and Pfizer. Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data … Read more

Here’s A New Coalition Dedicated To Fostering American Synthetic Biology Manufacturing

Here’s A New Coalition Dedicated To Fostering American Synthetic Biology Manufacturing

In April, three leading synthetic biology companies announced the launch of the Synthetic Biology (SynBio) Coalition (www.synbioco.com) to promote investment and support for the American synthetic biology industry. Synthetic biology is a field of science that involves redesigning microorganisms for useful purposes.  It is already being leveraged across many industries, including pharmaceuticals and medical treatments, … Read more

Liquid Biopsy Company Grail Presents Multi-Cancer Early Detection Results

Liquid Biopsy Company Grail Presents Multi-Cancer Early Detection Results

In June, GRAIL, Inc., presented the first results from the interventional PATHFINDER study evaluating Galleri™, a multi-cancer early detection (MCED) blood test. The results, presented at the 2021 ASCO Annual Meeting, support Galleri’s performance in clinical settings. The company also announced today that Galleri is now available in the U.S. by prescription only.  “The interim … Read more

Simulations Guide Rapid Engineering Of New Functions In Mammalian Cells

Simulations Guide Rapid Engineering Of New Functions In Mammalian Cells

A change of instructions in a computer program directs the computer to execute a different command. Similarly, synthetic biologists are learning the rules for how to direct the activities of human cells.  “Cells are intricate machines that have evolved many interacting circuits—sets of genes that coordinate functions like migration, metabolism, and cell division,” explains David … Read more

IPO: Verve Therapeutics Takes On Cardiovascular Disease Using Gene Editing

IPO: Verve Therapeutics Takes On Cardiovascular Disease Using Gene Editing

Verve Therapeutics, a biotech company innovating new approaches to the care of cardiovascular disease with single-course gene editing medicines, announced terms for its $201 million IPO on today. Insiders Wellington Management and Casdin Capital and new investor Fidelity have indicated an interest in purchasing up to an aggregate $75 million worth of shares in the … Read more